Epizyme (EPZM) Rating Increased to Strong-Buy at BidaskClub

Epizyme (NASDAQ:EPZM) was upgraded by BidaskClub from a “buy” rating to a “strong-buy” rating in a report issued on Thursday.

Other equities research analysts also recently issued reports about the stock. Zacks Investment Research upgraded shares of Epizyme from a “hold” rating to a “buy” rating and set a $8.25 price objective for the company in a research note on Tuesday, December 4th. ValuEngine upgraded shares of Epizyme from a “sell” rating to a “hold” rating in a research note on Saturday, December 15th. Oppenheimer set a $27.00 price objective on shares of Epizyme and gave the stock a “buy” rating in a research note on Thursday, November 15th. Wedbush reiterated an “outperform” rating and set a $21.00 price objective on shares of Epizyme in a research note on Monday, November 5th. Finally, Leerink Swann upgraded shares of Epizyme from a “market perform” rating to an “outperform” rating and set a $12.00 price objective for the company in a research note on Monday, January 7th. One analyst has rated the stock with a sell rating, two have given a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $19.44.

NASDAQ:EPZM opened at $12.89 on Thursday. Epizyme has a 12 month low of $5.14 and a 12 month high of $21.40. The firm has a market cap of $999.92 million, a PE ratio of -5.91 and a beta of 3.00.

A number of hedge funds and other institutional investors have recently bought and sold shares of EPZM. Bank of America Corp DE lifted its position in Epizyme by 19.8% during the second quarter. Bank of America Corp DE now owns 65,569 shares of the biopharmaceutical company’s stock valued at $889,000 after purchasing an additional 10,855 shares during the period. Northern Trust Corp lifted its position in Epizyme by 12.1% during the second quarter. Northern Trust Corp now owns 651,179 shares of the biopharmaceutical company’s stock valued at $8,823,000 after purchasing an additional 70,281 shares during the period. Alps Advisors Inc. lifted its position in Epizyme by 22.0% during the third quarter. Alps Advisors Inc. now owns 122,992 shares of the biopharmaceutical company’s stock valued at $1,304,000 after purchasing an additional 22,150 shares during the period. Jennison Associates LLC lifted its position in Epizyme by 0.7% during the third quarter. Jennison Associates LLC now owns 2,201,037 shares of the biopharmaceutical company’s stock valued at $23,331,000 after purchasing an additional 16,249 shares during the period. Finally, AXA acquired a new position in Epizyme during the third quarter valued at $714,000. Institutional investors own 73.72% of the company’s stock.

About Epizyme

Epizyme, Inc, a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer.

Read More: Index Funds

Analyst Recommendations for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.